BioCentury & Thomson Reuters to Convene the 20th Future Leaders in the Biotech Industry
REDWOOD CITY, CA and NEW YORK, NY, Apr 03, 2013 (Marketwired via COMTEX) --
BioCentury and Thomson Reuters will convene the 20th Annual Future
Leaders in the Biotech Industry in New York City this Friday, April
5th at 8 a.m. at the Millennium Broadway Hotel & Conference Center.
The event showcases a full slate of 45 biopharma companies
hand-picked on the basis of investor validation, upcoming milestones,
unpartnered assets and innovative science, informed by the collective
intelligence of BioCentury and Thomson Reuters.
Hundreds of life science investment professionals and pharmaceutical
business development and licensing executives have pre-registered for
the event. Walk-up registration is available at the Millennium
Broadway starting at 7:15 a.m. on Friday, April 5th.
Public companies at Future Leaders are collectively up 20% this year,
easily out-distancing the 16% jump in the BioCentury 100 Index as
well as the 11% gain in the Dow Jones Industrial Average and 10% gain
in the S&P 500. Over that same period, the aggregate market cap of
the Future Leaders public companies has grown by almost $1 billion,
from $5.3 billion to $6.2 billion.
The Future Leaders Class of 2013 includes 30 public and 15 private
companies that have raised $4.3 billion in capital, including $2
billion since the beginning of 2012.
The Class of 2013 showcases companies with a solid mix of innovative
science and platform assets and ample partnering opportunities.
Features for this year's slate include a track of companies nearing
critical proof-of-concept data events, fresh IPO stories, public
plays nearing commercialization milestones and upcoming Phase III
data sets and selected international companies with key value
inflection points. Key diseases areas include cancer, infectious
diseases, selected neurology and cardiovascular areas and
These Future Leaders have 6 marketed products, 12 programs in Phase
III/Registration, 58 programs in Phase II development, 40 programs in
Phase I development and at least 75 programs in preclinical
development. 125 programs are currently unpartnered.
"Biotech's bull run on Wall Street is not done," said BioCentury
Publisher Eric Pierce. "The Future Leaders Class of 2013 is aiming to
show how they can create more value for investors going forward."
Money managers attending the conference control over $400 billion in
equity assets, nearly $100 billion in healthcare assets, and almost
$15 billion in biotech assets.
The 2013 Presenting Companies
Presenting companies were screened
using Thomson Reuters and BioCentury industry analysis and
proprietary databases, including BioCentury's BCIQ online business
intelligence platform. The result is an independently selected mix of
companies with proven fundraising capacity, the prospect for key
partnerships and proximity to potentially transformational
milestones. (Stock symbols shown for publicly traded companies;
listed on NASDAQ unless noted).
Acceleron Pharma Inc.
Acetylon Pharmaceuticals Inc.
Alexza Pharmaceuticals Inc. (ALXA)
Curis Inc. (CRIS)
Cytokinetics Inc. (CYTK)
Cytori Therapeutics Inc. (CYTX; XMPA)
Cytos Biotechnology AG (CYTN)
Dicerna Pharmaceuticals Inc.
Endocyte Inc. (ECYT)
Forma Therapeutics Holdings LLC
Pharmaceuticals Inc. (FURX)
Galena Biopharma Inc. (GALE)
Heptares Therapeutics Ltd.
Horizon Pharma Inc.
ImmunoCellular Therapeutics Ltd. (IMUC)
Insmed Inc. (INSM)
Nanobiotix S.A. (NANO)
Navidea Biopharmaceuticals Inc.
Nuron Biotech Inc.
Omeros Corp. (OMER)
Pharmaceuticals Inc. (OGXI)
Onconova Therapeutics Inc.
Regulus Therapeutics Inc. (RGLS)
Therapeutics Inc. (RPRX)
Resverlogix Corp. (RVX)
Sucampo Pharmaceuticals Inc. (SCMP)
Pharmaceuticals Ltd. (4582)
TESARO Inc. (TSRO)
Pharmaceuticals Inc. (THLD)
Trimel Pharmaceuticals Corp. (TRL)
Trius Therapeutics Inc. (TSRX)
Ultragenyx Pharmaceutical Inc.
Vanda Pharmaceuticals Inc. (VNDA)
Verastem Inc. (VSTM)
See the Presenting Company schedule and additional program highlights
Top Sponsors Demonstrate Long-Term Commitment to Industry
prestigious group of 2013 sponsors is anchored by Gold Sponsors
Brinson Patrick Securities, Maxim Group and WBB Securities; Silver
Sponsors AstraZeneca plc and Bloom Burton & Co.; and luncheon sponsor
Flanders Investment and Trade.
This premier Wall Street event is one of two annual investor
conferences organized by BioCentury and Thomson Reuters. The next
conference, NewsMakers in the Biotech Industry, will take place in
New York City on September 27, 2013, at the Millennium Broadway Hotel
& Conference Center.
Since 1993, BioCentury Publications, Inc. has
provided essential biopharma industry intelligence to a global
audience of biotech and pharmaceutical executives, investors,
regulators and public policy makers, and the scientific community.
This audience has benefited from BioCentury's deep knowledge,
data-driven analysis, independent perspective and trustworthy content
available through the company's publications, data products and
collaborative industry conferences in the U.S., Europe and Asia.
BioCentury's titles include the flagship BioCentury(R), the Bernstein
Report on BioBusiness; its SciBX: Science-Business eXchange(TM)
translational science partnership with Nature Publishing Group; and
its BioCentury Extra(TM) online daily newspaper. These timely
journals are backed by BCIQ: BioCentury Online Intelligence(TM), an
online business intelligence resource. BioCentury also produces its
BioCentury This Week biotech public affairs television program in
partnership with the Gannett-owned WUSA9 CBS affiliate in Washington,
D.C. The program is aired in Washington each Sunday as part of the
WUSA9 Sunday Morning Power Block, on Public Broadcasting System
member stations in selected markets and distributed globally online
For more information, visit www.biocentury.com and
About Corporate Services
The Corporate Services business unit of Thomson Reuters provides
insight, analytics and communications solutions to Investor
Relations, Public Relations, Marketing and Internal Communications
professionals at thousands of companies worldwide. Our clients rely
on our desktop, mobile, advisory and multimedia solutions to: monitor
markets and peers, prioritize their outreach, reach and engage target
audiences and measure the impact of their programs.
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent
information for businesses and professionals. We combine industry
expertise with innovative technology to deliver critical information
to leading decision makers in the financial and risk, legal, tax and
accounting, intellectual property and science and media markets,
powered by the world's most trusted news organization. With
headquarters in New York and major operations in London and Eagan,
Minnesota, Thomson Reuters employs approximately 60,000 people and
operates in over 100 countries. Thomson Reuters shares are listed on
the Toronto and New York Stock Exchanges. For more information, go to
SOURCE: BioCentury Publications, Inc.
[ Back To TMCnet.com's Homepage ]